SABCS: Tamoxifen May Be Unfairly Blamed for Side Effects

Share this content:
SABCS: Tamoxifen May Be Unfairly Blamed for Side Effects
SABCS: Tamoxifen May Be Unfairly Blamed for Side Effects

FRIDAY, Dec. 9, 2016 (HealthDay News) -- Some high-risk women who take tamoxifen to prevent breast cancer may mistake naturally occurring nausea and vomiting for side effects of the drug and stop taking it, according to a study presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 6 to 10 in Texas.

A study of women taking tamoxifen in the United Kingdom found that one-third didn't continue the treatment for the recommended five years. Those who experienced nausea and vomiting were more likely to stop taking the drug than those without such symptoms.

However, women who were taking an inactive placebo and had the same symptoms were equally likely to stop. That suggests that some symptoms triggered by other causes were being mistaken for side effects of tamoxifen, according to the researchers.

"Our findings have implications for how doctors talk to patients about the benefits and side effects of preventive therapies such as tamoxifen," study author Samuel Smith, Ph.D., a Cancer Research UK fellow and university academic fellow at the University of Leeds, said in a Cancer Research news release. "It's important to manage expectations and provide accurate information on the likelihood of experiencing specific side effects, and how these differ from symptoms that women may experience anyway."

Press Release
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »